Distribution of resistant gram-positive organisms across the census regions of the United States and in vitro activity of tigecycline, a new glycylcycline antimicrobial

American Journal of Infection Control

Volumn 35, Issue 8, 2007, Pages 521-526

  Denys, Gerald A ^a   Koch, Kim M ^a   Dowzicky, Michael J ^b  

^a INDIANA UNIVERSITY HEALTH   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; AMPICILLIN; CEFTRIAXONE; IMIPENEM; LEVOFLOXACIN; LINEZOLID; MINOCYCLINE; PENICILLIN G; PIPERACILLIN PLUS TAZOBACTAM; TIGECYCLINE; VANCOMYCIN;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; ENTEROCOCCUS FAECIUM; GRAM POSITIVE BACTERIUM; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; STREPTOCOCCUS PNEUMONIAE; UNITED KINGDOM;

ANTI-BACTERIAL AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; GRAM-POSITIVE BACTERIA; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; METHICILLIN RESISTANCE; MICROBIAL SENSITIVITY TESTS; MINOCYCLINE; SENTINEL SURVEILLANCE; UNITED STATES; VANCOMYCIN RESISTANCE;

EID: 34948908732     PISSN: 01966553     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajic.2006.11.004     Document Type: Article

References (27)

1. McDonald L.C. Trends in antimicrobial resistance in health care-associated pathogens and effect on treatment. Clin Infect Dis 42 (2006) S65-S71
2. Hancock R.E. Mechanisms of action of newer antibiotics for gram-positive pathogens. Lancet Infect Dis 5 (2005) 209-218
3. Felmingham D. Tigecycline-the first glycylcycline to undergo clinical development: an overview of in vitro activity compared to tetracycline. J Chemother 17 Suppl 1 (2005) 5-11
4. Zhanel G.G., Karlowsky J.A., Rubinstein E., and Hoban D.J. Tigecycline: a novel glycylcycline antibiotic. Expert Rev Anti Infect Ther 4 (2006) 9-25
5. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, document M7-A6 (2003), National Committee for Clinical Laboratory Standards, Wayne, PA
6. Clinical and Laboratory Standards Institute. Performance standard for antimicrobial susceptibility testing, document M100-S15 (2005), Clinical and Laboratory Standards Institute, Wayne, PA
7. Wyeth Pharmaceuticals. Tygacil product insert. 2005. Wyeth Pharmaceuticals, Philadelphia, PA. Available at: http://www.tygacil.com. Accessed May 22, 2006.
8. Cosgrove S.E., Sakoulas G., Perencevich E.N., Schwaber M.J., Karchmer A.W., and Carmeli Y. Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 36 (2003) 53-59
9. Lodise T.P., and McKinnon P.S. Clinical and economic impact of methicillin resistance in patients with Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis 52 (2005) 113-122
10. DiazGranados C.A., Zimmer S.M., Klein M., and Jernigan J.A. Comparison of mortality associated with vancomycin-resistant and vancomycin-susceptible enterococcal bloodstream infections: a meta-analysis. Clin Infect Dis 41 (2005) 327-333
11. Graffunder E.M., and Venezia R.A. Risk factors associated with nosocomial methicillin-resistant Staphylococcus aureus (MRSA) infection including previous use of antimicrobials. J Antimicrob Chemother 49 (2002) 999-1005
12. Lodise T.P., McKinnon P.S., Tam V.H., and Rybak M.J. Clinical outcomes for patients with bacteremia caused by vancomycin-resistant Enterococcus in a level 1 trauma center. Clin Infect Dis 34 (2002) 922-929
13. Webb M., Riley L.W., and Roberts R.B. Cost of hospitalization for and risk factors associated with vancomycin-resistant Enterococcus faecium infection and colonization. Clin Infect Dis 33 (2001) 445-452
14. Diekema D.J., BootsMiller B.J., Vaughn T.E., Woolson R.F., Yankey J.W., Ernst E.J., et al. Antimicrobial resistance trends and outbreak frequency in United States hospitals. Clin Infect Dis 38 (2004) 78-85
15. Styers D., Sheehan D.J., Hogan P., and Sahm D.F. Laboratory-based surveillance of current antimicrobial resistance patterns and trends among Staphylococcus aureus: 2005 status in the United States. (http://www.ann-clinmicrob.com/content/5/1/2). Ann Clin Microbiol Antimicrob 5 (2006) 2
16. Karlowsky J.A., Jones M.E., Draghi D.C., Thornsberry C., Sahm D.F., and Volturo G.A. Prevalence and antimicrobial susceptibilities of bacteria isolated from blood cultures of hospitalized patients in the United States in 2002. (http://www.ann-clinmicrob.com/content/3/1/7). Ann Clin Microbiol Antimicrob 3 (2004) 7
17. Jones M.E., Draghi D.C., Thornsberry C., Karlowsky J.A., Sahm D.F., and Wenzel R.P. Emerging resistance among bacterial pathogens in the intensive care unit - a European and North American surveillance study (2000-2002). (http://www.ann-clinmicrob.com/content/3/1/14). Ann Clin Microbiol Antimicrob 3 (2004) 14
18. Streit J.M., Jones R.N., Sader H.S., and Fritsche T.R. Assessment of pathogen occurrences and resistance profiles among infected patients in the intensive care unit: report from the SENTRY antimicrobial surveillance program (North America, 2001). Int J Antimicrob Agents 24 (2004) 111-118
19. Fritsche T.R., Sader H.S., Stilwell M.G., Dowzicky M.J., and Jones R.N. Antimicrobial activity of tigecycline tested against organisms causing community-acquired respiratory tract infection and nosocomial pneumonia. Diagn Microbiol Infect Dis 52 (2005) 187-193
20. Bradford P.A., Weaver-Sands T., and Petersen P.J. In vitro activity of tigecycline against isolates from patients enrolled in phase 3 clinical trials of treatment for complicated skin and skin-structure infections and complicated intra-abdominal infections. Clin Infect Dis 41 (2005) S315-S332
21. Ellis-Grosse E.J., Babinchak T., Dartois N., Rose G., and Loh E. The efficacy and safety of tigecycline in the treatment of skin and skin-structure infections: results of 2 double-blind phase 3 comparison studies with vancomycin-aztreonam. Clin Infect Dis 41 (2005) S341-S353
22. Bonora M.G., Solbiati M., Stepan E., Zorzi A., Luzzani A., Catania M.R., et al. Emergence of linezolid resistance in the vancomycin-resistant Enterococcus faecium multilocus sequence typing C1 epidemic lineage. J Clin Microbiol 44 (2006) 1153-1155
23. Anderegg T.R., Sader H.S., Fritsche T.R., Ross J.E., and Jones R.N. Trends in linezolid susceptibility patterns: report from the 2002-2003 worldwide Zyvox annual appraisal of potency and spectrum (ZAAPS) program. Int J Antimicrob Agents 26 (2005) 13-21
24. Pottumarthy S., Fritsche T.R., Sader H.S., Stilwell M.G., and Jones R.N. Susceptibility patterns of Streptococcus pneumoniae isolates in North America (2002-2003): contemporary in vitro activities of amoxicillin/clavulanate and 15 other antimicrobial agents. Int J Antimicrob Agents 25 (2005) 282-289
25. Doern G.V., Richter S.S., Miller A., Miller N., Rice C., Heilmann K., et al. Antimicrobial resistance among Streptococcus pneumoniae in the United States: have we begun to turn the corner on resistance to certain antimicrobial classes?. Clin Infect Dis 41 (2005) 139-148
26. Mera R.M., Miller L.A., Daniels J.J., Weil J.G., and White A.R. Increasing prevalence of multidrug-resistant Streptococcus pneumoniae in the United States over a 10-year period: Alexander Project. Diagn Microbiol Infect Dis 51 (2005) 195-200
27. Tleyjeh I.M., Tlaygeh H.M., Hejal R., Montori V.M., and Baddour L.M. The impact of penicillin resistance on short-term mortality in hospitalized adults with pneumococcal pneumonia: a systematic review and meta-analysis. Clin Infect Dis 42 (2006) 788-797